The coronavirus disease 2019 (COVID-19) is an acute respiratory disease caused by the novel RNA virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first report of SARS-CoV-2-infected patients in Wuhan, China, in December 2019, the number of persons with COVID-19 has markedly increased worldwide. As we approach 2022, we are experiencing a big wave of COVID-19 caused by SARS-CoV-2 variants (i.e., delta, lambda, mu, and omiclone). Approximately 80% of SARS-CoV-2-infected subjects is mild to moderate (stage I) (Fig. 1). The remaining 20% may convert to severe clinical stages in about 1 week (stage II). Subsequently, a part of stage II (~5% of total) may convert to stage III, ultimately resulting in intubation or death (Fig. 1) [1]. Furthermore, SARS-CoV-2 infection seems to cause detrimental effects in the central nervous system (CNS), resulting in psychiatric and neurological symptoms [2,3,4,5]. A nationwide longitudinal study in China showed a long-term mental health impact in persons with COVID-19 [6].

Fig. 1: The clinical course of COVID-19 and early intervention by fluvoxamine.
figure 1

The three escalating phases of COVID-19 progression, with associated symptoms. Approximately 80% of SARS-CoV-2-infected subjects is mild to moderate (stage I). The remaining 20% may convert to severe clinical stages in about 1 week (stage II). Subsequently, the part of stage II (~5% of total) may convert to stage III, ultimately resulting in intubation or death. Being a cheap antidepressant, fluvoxamine can be used in the early-stage of COVID-19. However, its use for COVID-19 was not yet approved. ARDS acute respiratory distress syndrome, SIRS systemic inflammatory response syndrome. A slight modification with Fig. 1 in the reference [1]. Some materials of the figure have been designated using resources from

With the current COVID-19 pandemic, drug repurposing is an important approach to discover promptly prophylactic or therapeutic drugs for persons with COVID-19 [7,8,9,10]. A number of candidates have been investigated in SARS-CoV-2-infected patients since early 2020 [11]. Studies using in vitro or in silico assays discovered a number of candidates from approved inexpensive drugs. However, most candidates have no beneficial effects in in vivo models [12] or SARS-CoV-2-infected patients [13]. According to clinical trial reports, some promising candidates, such as hydroxychloroquine, lopinavir-ritonavir, and ivermectin, were ineffective in the treatment of patients with COVID-19 [14,15,16,17,18,19].

Increasing clinical data suggest that the use of antidepressants, such as selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI), might be associated with a reduced risk of clinical deterioration in SARS-CoV-2-infected patients. In November 2020, Dr. Lenze et al. reported that the SSRI fluvoxamine could prevent clinical deterioration in early-stage COVID-19 outpatients [20]. Subsequently, Hoertel et al. reported that the use of antidepressants, such as SSRIs and SNRIs, may be associated with reduced risk of intubation or death in hospitalized SARS-CoV-2-infected patients [21]. At present, the old SSRI fluvoxamine may be new hope for the COVID-19 pandemic [22].

In this article, we review the mechanisms of action of fluvoxamine and other antidepressants for COVID-19 and discuss a possible link between maternal infection of SARS-CoV-2 and the risk for neuropsychiatric disorders in offspring, since the number of SARS-CoV-2-infected pregnant women has been increasing worldwide.

The use of antidepressants and antipsychotics in COVID-19 patients


In November 2020, Dr. Lenze et al. reported that the SSRI fluvoxamine could prevent clinical deterioration in adult outpatients with COVID-19. In the study, clinical deterioration did not occur in the fluvoxamine group (n = 80), but occurred in six from the placebo group (n = 72) [20]. This study’s sample size was small, hence, strongly encouraged further trials using a large sample size.

In February 2021, Seftel and Boulware [23] reported a prospective, non-randomized observational cohort study at the Golden Gate Fields horse racing track in Berkeley, California. Hospitalization incidence in the fluvoxamine-treated (n = 65) and observation-alone (n = 48) groups was 0 and 6, respectively. Among the six patients of the observation-alone group, two were required to stay in the intensive care unit (ICU) with mechanical ventilation, of which one died [23]. On April 23, 2021, fluvoxamine was added to the US National Institutes of Health (NIH) COVID-19 Guidelines Panel, although evidence for fluvoxamine efficacy was insufficient.

In October 2021, Reis et al. [24] reported a placebo-controlled, randomized, adaptive, platform trial of fluvoxamine in unvaccinated and symptomatic SARS-CoV-2-infected Brazilian adult patients. Patients enrolled in this trial have a known risk factor for severe disease progression [24] and were randomly assigned to either fluvoxamine (100 mg twice daily for 10 days) or a placebo. The proportion of patients observed in an emergency room for 6 h or hospitalized was lower for the fluvoxamine group (n = 741) compared to the placebo group (n = 756) (relative risk = 0.68, 95% Bayesian credible interval = 0.52–0.88) [24]. There was one death in the fluvoxamine group and 12 in the placebo group. There were no significant differences in the number of treatment-emergent adverse events between the two groups [24]. This study with a large sample size shows that the treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early-diagnosed COVID-19 could reduce the need for extended emergency room observation or hospitalization. In this TOGETHER study, other candidates, such as hydroxychloroquine, lopinavir-ritonavir, metformin, and ivermectin, had no beneficial effects for patients with COVID-19 [16, 24, 25]. A recent open-label, prospective cohort study using ICU patients (n = 51) with COVID-19 showed that fluvoxamine (100 mg three times daily for 15 days) significantly [hazard ratio (HR) = 0.58, 95% CI = 0.36–0.94, P = 0.027] decreased the mortality compared to the matched control group [26].

In November 2021, Oskotsky et al. [27] reported the results of retrospective cohort study of COVID-19 patients treated with SSRIs using electronic health records of 87 health care centers across the US. This study included COVID-19 patients (n = 470) receiving fluoxetine only, COVID-19 patients (n = 481) receiving fluoxetine or fluvoxamine, and COVID-19 patients (n = 2898) receiving other SSRIs. Compared with matched untreated control COVID-19 patients, relative risk of mortality was reduced among patients treated with any SSRI (relative risk = 0.92, 95% CI = 0.85–0.99, adjusted P = 0.03), fluoxetine (relative risk = 0.72, 95% CI = 0.54–0.97, adjusted P = 0.03), and fluoxetine or fluvoxamine (relative risk = 0.74, 95% CI = 0.55–0.99, adjusted P = 0.04). In contrast, there was not significant (relative risk = 0.92, 95% CI = 0.84–1.00, adjusted P = 0.06) between SSRIs other than fluoxetine or fluvoxamine and risk of death. Among SSRIs, fluoxetine and fluvoxamine may be prophylactic SSRIs for COVID-19.

Collectively, fluvoxamine could likely be a prophylactic drug for early-stage SARS-CoV-2-infected patients [7, 22]. However, further multicenter randomized double-blind studies with a large sample size are needed.

Other antidepressants

An observational multicenter retrospective cohort study in France revealed a significant association between antidepressant use and reduced risk of intubation or death (HR = 0.56, 95% CI = 0.43–0.73, P < 0.001) in COVID-19 hospitalized patients [21]. There were significant associations between the use of SSRIs (HR = 0.51, 95% CI = 0.316–0.72, P < 0.001) and non-SSRIs (HR = 0.65, 95% CI = 0.45–0.93, P = 0.018). Among SSRIs used in this study, the authors showed the results of citalopram (n = 21, HR = 0.50, 95% CI = 0.14–1.76, P = 0.283), escitalopram (n = 63, HR = 0.46, 95% CI = 0.27–0.79, P = 0.005), fluoxetine (n = 30, HR = 0.26, 95% CI = 0.09–0.75, P = 0.013), paroxetine (n = 63, HR = 0.53, 95% CI = 0.30–0.94, P = 0.030), and sertraline (n = 22, HR = 0.75, 95% CI = 0.29–1.95, P = 0.554). Only one subject treated with fluvoxamine was included in this study since it was unpopular in France. Interestingly, among the 577 patients admitted to the ICU, antidepressant use was significantly associated with reduced risk of intubation or death. In an Exploratory analysis, three SSRIs (escitalopram, fluoxetine, and paroxetine) were significantly associated with reduced risk of intubation or death [21].

Furthermore, in an observational study in Italy, hospitalized COVID-19 patients (n = 34) treated with antidepressants (i.e., sertraline, escitalopram, citalopram, paroxetine, venlafaxine, and duloxetine) before admission until discharge from the hospital had a lower incidence of severe acute respiratory distress syndrome (ARDS) than those (n = 368) treated without antidepressant [28]. Interestingly, blood levels of interleukin-6 (IL-6) from recovered patients of the antidepressant-treated group were significantly lower than those of recovered patients of not-treated group [28]. It suggests that modulation of IL-6 production by antidepressant may play a role in the beneficial effects of the antidepressant-treated group. These data strongly encourage future randomized, double-blind trials using these SSRIs (or SNRIs) for COVID-19.

In a recent systematic review and meta-analysis, any mental disorder (i.e., psychotic, mood, and anxiety disorders) present in COVID-19 patients was associated with an increased risk of mortality (odds ratios = 2.00, 95% CI = 1.58–2.54). Mortality was associated with the use of antipsychotics (odds ratios = 3.71, 95% CI = 1.74–7.91), anxiolytics (odds ratios = 2.58, 95% CI = 1.22–5.44), and antidepressants (odds ratios = 2.23, 95% CI = 1.06–4.71) [29]. In contrast to antipsychotics and anxiolytics, mortality risk associated with antidepressants was not increased after the adjustment for age, sex, and other covariables. This study shows that antidepressant exposure was not associated with COVID-19 mortality, whereas antipsychotic and anxiolytic exposure was associated with COVID-19 mortality [29].

El-Battrawy et al. [30] reported a systematic analysis of concomitant arterial hypertension in COVID-19 patients. The mortality rate (29.6%) of patients with concomitant hypertension (n = 2850) was significantly higher than that (11.3%) of patients without arterial hypertension (n = 2960), suggesting a risk factor for mortality. By contrast, antidepressant use at admission (n = 746) might be a positive independent predictor of mortality (HR = 2.94, 95% CI = 1.60–5.43, P = 0.001) [30], inconsistent with the previous reports [21, 29]. The detailed information (i.e., SSRI or SNRI) of the antidepressants used in this article was not disclosed.

Collectively, antidepressant use might seem to be associated with reduced risk for a severe clinical course in COVID-19 patients. Further randomized, double-blind study using a large sample size is needed to identify specific antidepressants for COVID-19.

Typical antipsychotic drugs: haloperidol and chlorpromazine

A multicenter observational study in France showed that haloperidol use (n = 39) was not associated (HR = 1.30, 95% CI = 0.74–2.28, P = 0.335) with the risk of intubation or death in hospitalized COVID-19 adult patients (n = 15,121) [31]. Furthermore, Hoertel et al. [32] reported an observational study of chlorpromazine among COVID-19 hospitalized patients of (n = 14,340) [32]. The primary analysis showed no significant association (HR = 2.01, 95% CI = 0.75–5.40, P = 0.163) between chlorpromazine use (n = 55) and mortality in hospitalized COVID-19 adult patients. Collectively, these two reports suggest that the use of antipsychotic drugs (haloperidol and chlorpromazine) might not be associated with the reduced risk of intubation or death in COVID-19 patients. As aforementioned, the use of antipsychotics was associated with the mortality of COVID-19 patients [29]. Furthermore, the use of antipsychotic drugs could cause extrapyramidal side effects due to potent dopamine D2 receptor antagonism (Table 1) [7, 33]. It is, therefore, unlikely that the use of antipsychotic drugs should be recommended for the treatment of COVID-19 patients.

Table 1 Affinity and pharmacology of the antidepressants and antipsychotics for sigma-1 receptor and action at ASM.

Mechanisms of action of fluvoxamine and other antidepressants

Inhibition of serotonin transporter

The primary action of all antidepressants, such as SSRIs and SNRIs, is serotonin transporter inhibition in the brain, resulting in increasing levels of serotonin in the synaptic cleft. The human platelets have a high density of serotonin transporter [34,35,36]. Through serotonin transporter inhibition in the platelets by SSRIs or SNRIs, these antidepressants could reduce platelet aggregation, contributing to their effects [37]. Preclinical and clinical studies show that SSRIs or SNRIs have anti-inflammatory effects in rodents and depressed patients [38,39,40,41,42]. Therefore, antidepressants can possibly have anti-inflammatory effects through serotonin transporter inhibition (Fig. 2). It is also reported that fluvoxamine attenuates inflammation on injured striatal neurons by increasing anti-inflammatory cytokines while decreasing pro-inflammatory cytokines in the brain of Parkinson’s disease model [43]. Furthermore, fluvoxamine inhibits carrageenan-induced inflammation in rat paw edema [44] and fluvoxamine attenuated experimental autoimmune encephalomyelitis severity in a rat model of multiple sclerosis [45]. Collectively, it seems that fluvoxamine has potent anti-inflammatory effects in vitro and in vivo models.

Fig. 2: Proposed biological mechanisms of fluvoxamine in the treatment of COVID-19 patients.
figure 2

SARS-CoV-2 binds to ACE2 receptor on the cells, resulting in acid sphingomyelinase (ASM) activation, converting sphingomyelin to ceramide. The ASM/ceramide system can facilitate viral entry. Antidepressants, such as fluvoxamine, inhibit ASM and ceramide-enriched membrane domain formation, resulting in decreased viral entry. Sigma-1 receptor plays a role in the SARS-CoV-2 replication. Through sigma-1 receptor chaperone activity, the sigma-1-receptor agonist fluvoxamine may attenuate SARS-CoV-2 replication and SARS-CoV-2 replication-induced ER stress in cells, resulting in a blockade against inflammatory events (i.e., cytokine storm). Moreover, fluvoxamine has anti-inflammatory effects by serotonin transporter inhibition in the body. Thus, early intervention using fluvoxamine may block or delay clinical deterioration in COVID-19 patients. A slight modification with Fig. 1 in the ref. [22]. Some materials of the figure have been designated using resources from

The lung has a high expression of the serotonin transporter in rodents and humans [46,47,48], suggesting that potent vasoconstrictor serotonin bioavailability is predominantly regulated by the serotonin transporter in the lung endothelium [49]. Therefore, antidepressants, such as SSRIs and SNRIs, may influence COVID-19 patients’ lung function. However, further study is needed.

Although all antidepressants can block the body’s serotonin transporter, they did not show similar beneficial effects for COVID-19 patients. Therefore, it is unlikely that serotonin transporter inhibition by fluvoxamine may play a major role in its beneficial effects for COVID-19 patients. However, anti-inflammatory effects of serotonin transporter inhibition may, in part, play a role in its beneficial effects (Fig. 2). A recent observational study showed that treatment with SSRIs such as sertraline, paroxetine, fluvoxamine, and fluoxetine showed antidepressant effects in patients (n = 60) with a post-COVID-19 depression [50], suggesting the potential use of SSRIs in the treatment of post-COVID-19 depression.

Sigma-1 receptor

Role of sigma-1 receptor in the replication of SARS-CoV-2

In 2013, Friesland et al. [51] reported the endoplasmic reticulum (ER) protein sigma-1 receptor discovery as a cellular factor, mediating the early steps of viral RNA replication. The sigma-1 receptor expression is not rate-limiting for persistent hepatitis C virus (HCV) RNA replication. However, it is rate-limiting for HCV RNA replication without impairing primary translation [51]. Thus, the sigma-1 receptor may be essential for virus replication at the early-stage of virus infection [52].

A recent study using the SARS-CoV-2 human protein-protein interaction map identified 332 high-confidence protein-protein interactions between SARS-CoV-2 and human proteins [53]. A number of compounds for sigma-1 and sigma-2 receptors were identified as promising inhibitors for SARS-CoV-2 replication [53]. Subsequently, the same group revealed the sigma-1 receptor (encoded by SIGMAR1) as a functional host dependency factor for SARS-CoV-2. Knockout (KO) or SIGMAR1 knockdown produced robust reductions in SARS-CoV-2 replication, indicating the sigma-1 receptor’s key role in SARS-CoV-2 replication [54]. Sigma-1 receptor is known to be enriched in lipid rafts colocalized with viral replicate proteins, such as non-structural protein 6 (NSP6). Taken together, sigma-1 receptor might interfere with the early steps of virus-induced host cell reprogramming [55]. Moreover, through the chaperone activity, sigma-1 receptor agonists may protect against mitochondrial damage and ER stress in response to SARS-CoV-2 infection [56]. Therefore, sigma-1 receptor ligands could likely be useful for an early intervention for COVID-19 patients [55, 56]. However, which pharmacological activity (i.e., agonist or antagonist) of sigma-1 receptor ligands is responsible for the SARS-CoV-2 replication activity remains uncertain [7].

Sigma-1 receptor and antidepressants

In 1996, our group reported the binding affinity of SSRIs for the sigma-1 receptor (Table 1) [57]. Some SSRIs, such as fluvoxamine, sertraline, fluoxetine, and citalopram, have a high to moderate affinity for sigma-1 receptors in the rat brain (Table 1). In contrast, the SSRI paroxetine, tricyclic antidepressants (imipramine and desipramine), SNRIs (duloxetine, venlafaxine, and milnacipran), and mirtazapine were very weak for the sigma-1 receptor (Table 1). This study suggests that the sigma-1 receptor may play a role in the mechanisms of action of some SSRIs, such as fluvoxamine, with high affinity. The sigma-1 receptor cloned by Hanner et al. [58] shared homology with fungal proteins involved in sterol synthesis. Subsequently, Hayashi and Su [59] reported that it could function as a novel ER molecular chaperone, regulating a variety of cellular functions. Sigma-1 receptor agonists (i.e., fluvoxamine and fluoxetine) promote the sigma-1 receptor dissociation from another ER chaperone, binding immunoglobulin protein (BiP)/GRP78 (glucose-regulated protein 78), resulting in sigma-1 receptor chaperone activity in the cells. In contrast, sigma-1 receptor antagonists (i.e., haloperidol, NE-100) reinforce the association, blocking the action of sigma-1-receptor agonists [59, 60]. Thus, sigma-1 receptor agonists can produce chaperone activity, resulting in the protection against ER stress associated with a number of diseases.

Subsequent studies suggest that fluvoxamine is a potent agonist for sigma-1 receptor. In the assay, fluvoxamine, fluoxetine, and escitalopram significantly potentiated nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells, and these SSRIs’ effects were antagonized by selective sigma-1 receptor antagonist NE-100 (Table 1) [61,62,63]. Moreover, the effects of fluvoxamine and fluoxetine on NGF-induced potentiation of neurite outgrowth were antagonized by sertraline, suggesting that sertraline may be a sigma-1 receptor antagonist (Table 1) [63]. A positron emission tomography using [11C]SA4503 study showed that fluvoxamine binds to the sigma-1 receptor in the intact human brain at therapeutic doses [64]. Collectively, fluvoxamine is a likely unique SSRI with potent sigma-1 receptor agonism [65,66,67,68].

In 2019, Rosen et al. [69] demonstrated sigma-1 receptor’s essential role in inflammation and sepsis mouse models. The mortality (62%) of sigma-1 receptor KO mice post-injection of lipopolysaccharide (LPS: 5 mg/kg) was significantly higher than that (9%) of wild-type mice. Furthermore, serum levels of pro-inflammatory cytokines [i.e., IL-6, tumor necrosis factor-α (TNF-α)] in KO mice after LPS (5 mg/kg) injection were significantly higher than those of wild-type mice [69]. The data suggest that sigma-1 receptor plays a key role in systemic inflammation and cytokine production. Interestingly, treatment with fluvoxamine could protect against LPS (6 mg/kg)-induced lethal septic shock [69]. Collectively, it is likely that the potent sigma-1 receptor agonist fluvoxamine might ameliorate ER stress-associated inflammatory events (i.e., cytokine storm) due to SARS-CoV-2 replication (Fig. 2) [7, 22].

As mentioned above, haloperidol or sertraline use may not be associated with the risk of intubation or death in COVID-19 hospitalized adult patients, although the sample size is too small [21, 31]. Since haloperidol and sertraline are sigma-1 receptor antagonists (Table 1), sigma-1 receptor antagonists seem to not have beneficial effects in COVID-19 patients. However, further study is needed.

Given the key role of the chaperone activity by sigma-1 receptor agonist in SARS-CoV-2 replication, it is possible that the SSRIs (i.e., fluvoxamine, fluoxetine, escitalopram) with sigma-1 receptor agonisms could be COVID-19 prophylactic drugs. Current data of fluoxetine and escitalopram for COVID-19 are from an observational study in France [21].

Interaction of steroids with sigma-1 receptor

Steroids are synthesized from cholesterol in the CNS and peripheral nervous system. Pregnenolone (PREG) synthesized from cholesterol is converted into 17α-hydroxypregnenolone and then dehydroepiandrosterone (DHEA). Both PREG and DHEA are found, in part, as sulfate esters (PREG-S and DHEA-S). DHEA is metabolized to testosterone, the key male sex hormone, and PREG is converted into progesterone [70]. DEHA, the most abundant endogenous steroid, is a sigma-1 receptor agonist with moderate affinity, whereas progesterone and testosterone are sigma-1 receptor antagonists.

It is well known that illness severity in male COVID-19 patients is consistently higher than that of women [71, 72]. There are sex-specific mechanisms, including hormone-related expression of genes encoding for SARS-CoV-2 entry receptors (i.e., angiotensin-converting enzyme 2 (ACE2) receptor) and immune responses to SARS-CoV-2 [73]. Being known to regulate the immune system, sex steroids, such as testosterone, estradiol, and progesterone, may play a role in gender differences in clinical courses of SARS-CoV-2-infected people.

A case-controlled study in Italy showed that lower testosterone levels in male COVID-19 patients (n = 286) were associated with a higher risk of ICU admission and death outcomes [74]. Subsequently, a single-center cohort study showed that lower testosterone levels during hospitalization were associated with increased disease severity and inflammation in men with severe COVID-19 (n = 66) [75]. In this study, testosterone levels were inversely associated with levels of IL-6, C-reactive protein (CRP), interleukin 1 receptor antagonist, hepatocyte growth factor, and interferon γ-inducible protein 10. In contrast, estradiol and insulin-like growth factor 1 (IGF-1) were not associated with the severity in men with COVID-19. There were no changes in testosterone, estradiol, and IGF-1 in women with and without severe COVID-19. Furthermore, male COVID-19 patients with a severe course of infection had lower serum testosterone levels [75], which were also associated with elevated CRP and IL-6, lower cholesterol levels, and increased morbidity and mortality [75]. Collectively, lower testosterone levels in men with COVID-19 are linked to more advanced immune activation, increasing the risk for ICU admission or death. The underlying mechanisms for the association between low testosterone and severe clinical course in male COVID-19 patients remain unknown. Although testosterone is an antagonist with moderate affinity for the sigma-1 receptor, whether sigma-1 receptor plays a role in the action of testosterone for COVID-19 remains unclear.

Progesterone’s anti-inflammatory actions are well recognized. It has various alleviating effects, from SARS-CoV-2 entry to recovery: reversing hypoxia, stabilizing blood pressure, controlling thrombosis, balancing electrolytes, reducing the viral load, immune response regulation, damage repair, and debris clearance among others [76, 77]. Hence, progesterone use for COVID-19 patients is recommended [77]. A pilot randomized open-label controlled study showed beneficial effects of progesterone (100 mg twice daily for up to 5 days) in moderate to severe COVID-19 hospitalized male patients [78]. Although progesterone is an antagonist with a high affinity for the sigma-1 receptor, whether sigma-1 receptor plays a role in the action of progesterone for COVID-19 remains unclear.

DHEA (or DHEA-S), a testosterone precursor, is a sigma-1 receptor agonist [62, 79]. PREG (or PREG-S), a progesterone precursor, is also a weak agonist for sigma-1 receptor. Therefore, it is of interest to measure blood levels of these steroids in COVID-19 patients.

Acid sphingomyelinase (ASM)

The acid sphingomyelinase (ASM) and ceramide play key roles in bacterial and viral infections. ASM is a glycoprotein that functions as a lysosomal hydrolase, catalyzing sphingomyelin degradation to phosphorylcholine and ceramide (Fig. 2) [80,81,82]. Ceramide is also known to facilitate viral entry despite sphingosine’s blockage. Thus, ASM is essential for ceramide generation. Its functional inhibition can reduce virus entry into the epithelial cells. SARS-CoV-2 activates the ASM/ceramide system, resulting in the formation of ceramide-enriched membrane domains that serve viral entry and infection of clustering ACE2, the cellular receptor of SARS-CoV-2 [83].

Many antidepressants, such as fluoxetine, sertraline, paroxetine, and amitriptyline, are reported to inhibit ASM activity, suggesting a possible role of ASM in the effects of antidepressants [84,85,86]. Antidepressants (i.e., amitriptyline, imipramine, fluoxetine, sertraline, and escitalopram) with ASM inhibition prevented the infection of cultured cells or freshly isolated human nasal epithelial cells with SARS-CoV-2 (Table 1) [87, 88]. Fluvoxamine is also known to be an inhibitor of ASM [89].

A recent observational multicenter study (n = 2846) showed association (HR = 0.71, 95% CI = 0.58–0.87, P < 0.01) between the use of functional inhibitors of ASM and reduced risk of intubation or death among severe COVID-19 hospitalized patients (n = 277) [90]. Among the antidepressants, escitalopram use was significantly associated with a reduced risk of severe clinical stage [90]. However, other antidepressants, including amitriptyline, clomipramine, duloxetine, fluoxetine, paroxetine, and sertraline (Table 1), did not reach statistical significance, possibly due to restricted statistical power [90]. As mentioned above, fluvoxamine was not included.

The typical antipsychotic drug chlorpromazine is an ASM inhibitor (Table 1), and chlorpromazine blocked SARS-CoV-2 replication in human cells [91]. Hoertel et al. [32] reported an observational study of typical antipsychotic drug chlorpromazine in COVID-19 hospitalized patients (n = 14,340) [32]. In the primary analysis, there was no significant association (HR = 2.01, 95% CI = 0.75–5.40, P = 0.163) between chlorpromazine use (n = 55) and mortality in hospitalized COVID-19 adult patients. Since chlorpromazine is an ASM functional inhibitor [32], ASM inhibition unlikely plays a major role in the protective effects for the risk of death in COVID-19 patients. Nonetheless, further randomized, double-blind study using a large sample size is needed.

Considering the role of sigma-1 receptor and ASM in biological actions of SARS-CoV-2 in cells (Fig. 2) [92], escitalopram may be a prophylactic or therapeutic drug for SARS-CoV-2-infected patients. However, a further clinical study using a large sample size is needed.

Other mechanisms


Melatonin is naturally synthesized in the pineal gland and immune cells from the amino acid tryptophan. It may be a potential drug for COVID-19, since it has anti-inflammatory, immunomodulatory, and antioxidant mechanisms [93, 94]. It is proposed that increased melatonin levels by cytochrome P450 enzyme CYP1A2 inhibition by fluvoxamine may play a role in the anti-inflammatory effects of fluvoxamine [37, 95].


The inhibition of phospholipid production is suggested to be associated with the inhibition of coronavirus replication [96]. Among the many candidates investigated, sertraline and chlorpromazine were examples of high phospholipidosis-inducing drugs for SARS-CoV-2 in vitro [12]. Unfortunately, all candidates, including sertraline, were not efficacious in in vivo model. However, the only FDA-approved remdesivir showed beneficial effects in the same model. These findings strongly suggest that candidates discovered in in vitro assay do not translate in vivo. In the observational studies in France, sertraline or haloperidol use was not associated with reduced risk of intubation or death [21, 31]. Collectively, it is unlikely that phospholipid production-inhibiting compounds may be potential prophylactic or therapeutic drugs for COVID-19.

Lysosomal trafficking

Other mechanisms include reduction in decreased mast cell degranulation and modulation with lysosomal viral trafficking [37]. In a recent study, a sub-therapeutic concentration (80 nM) of fluvoxamine results in a significant rearrangement of membrane trafficking in a human cell line, enhancing endocytic uptake of SARS-CoV-2 spike proteins [97].

In a new study, antidepressants (i.e., fluvoxamine, fluoxetine, citalopram, paroxetine, venlafaxine, reboxetine, clomipramine, and imipramine) had antiviral effects in SARS-CoV-2-infected cells [98]. However, the precise mechanisms underlying their antiviral effects remain unknown.

Pregnant women

Pregnant women infected with SARS-CoV-2 and mental health in offspring

Epidemiological studies suggest that maternal immune activation (MIA), such as maternal infection, might be associated with the risk for neuropsychiatric disorders, such as autism spectrum disorder (ASD) and schizophrenia in offspring [99,100,101]. For example, a population-based birth cohort study (born in 1959–1966) showed that the risk of schizophrenia was increased sevenfold for influenza exposure during the first trimester, but not the second or third trimester [102]. In a study using all children born in Denmark in 1980–2005, hospital admission due to maternal viral and maternal bacterial infections in the first and second trimesters, respectively, were associated with the onset of ASD in the offspring [103]. Collectively, maternal infection during the first trimester is possibly a risk factor for ASD and schizophrenia in offspring.

During the COVID-19 pandemic, the number of SARS-CoV-2-infected pregnant women has been increasing worldwide. There are several reports showing higher levels of inflammatory biomarkers such as CRP in pregnant women with COVID-19 [104,105,106], suggesting MIA in pregnant women with COVID-19. Considering the risk for maternal infection on neuropsychiatric disorders in offspring, offspring follow-up after maternal infection by SARS-CoV-2 is important (Fig. 3). It is of great interest to compare the incidence of neuropsychiatric disorders in offspring of pregnant women with or without COVID-19.

Fig. 3: The risk for neuropsychiatric disorders in offspring after maternal COVID-19 infection.
figure 3

Maternal infection by SARS-CoV-2 causes inflammatory events in pregnant women, resulting in higher levels of inflammatory biomarkers (i.e., CRP, IL-6, and TNF-α) in the blood and tissues. Given the role of maternal immune activation in the risk of neuropsychiatric disorders, such as ASD and schizophrenia in offspring, a follow-up study of COVID-19-infected pregnant women and their children is needed. Furthermore, early intervention using nutrition with anti-inflammatory actions may be needed to block the onset of neuropsychiatric disorders. A slight modification with Fig. 1 in the ref. [113]. Some materials of the figure have been designated using resources from and

It is shown that pregnant and recently pregnant women are at an increased risk for severe clinical course from COVID-19 than nonpregnant women [107, 108]. In the multinational cohort study of pregnant women (n = 2130) in 18 countries, women with COVID-19 were at higher risk for preeclampsia/eclampsia [relative risk (RR) = 1.76; 95% CI = 1.27–2.43], severe infections (RR = 3.38, 95% CI = 1.63–7.01), ICU admission (RR = 5.04, 95% CI = 3.13–8.10), maternal mortality (RR = 22.3, 95% CI = 2.88–172), preterm (RR = 1.59, 95% CI = 1.30–1.94) and medically indicated preterm births (RR = 1.97, 95% CI = 1.56–2.51), severe neonatal morbidity index (RR = 2.66, 95% CI = 1.69–4.18), and severe perinatal morbidity and mortality index (RR = 2.14, 95% CI = 1.66–2.75) [108]. More than one half of pregnant women with COVID-19 are asymptomatic or mild. However, a part of them is converted to severe stages. Therefore, vaccination for SARS-CoV-2 in pregnant women is important to prevent clinical deterioration post-infection. Although the safety of the mRNA COVID-19 vaccine in pregnant women was reported [109], maternal vaccination effects on offspring remain unclear. Therefore, following up their children postdelivery from mothers with COVID-19 is important (Fig. 3).

Preclinical and clinical studies suggest that nutritional intervention with anti-inflammatory compounds (i.e., sulforaphane, omega-3 polyunsaturated fatty acids, choline, and vitamin D) may prevent the onset of neuropsychiatric disorders in offspring after MIA [110,111,112,113,114,115,116]. Collectively, we suggest that nutritional intervention may be a useful approach for the prevention of neuropsychiatric disorders in offspring after maternal SARS-CoV-2 infection (Fig. 3) [113].

The use of antidepressants in pregnant women with COVID-19

Increasing evidence suggests that the use of antidepressants during pregnancy might be associated with the risk of ASD in offspring [117,118,119]. Conversely, in a recent systematic umbrella review, maternal use of antidepressants appears to be safe for psychiatric disorder treatment [120], although further study is needed. A recent meta-analysis showed that neither psychiatric control or discordant sibling designs supported the association between prenatal antidepressant exposure and ASD [121].

A recent meta-analysis of pregnant women during the COVID-19 pandemic showed high prevalence of depression and anxiety in pregnant women [122]. According to the NIH COVID-19 Treatment Guideline, fluvoxamine is not thought to increase the risk of congenital abnormalities. However, data on fluvoxamine use during pregnancy are limited. The risk of fluvoxamine use should be balanced with potential benefit. If pregnant women with COVID-19 use antidepressants as a treatment for their mood disorders or prophylactic treatment for the clinical deterioration of COVID-19, a mental health follow-up for the offspring is also important.


As we discussed in this article, the mechanisms of action of fluvoxamine for COVID-19 are complex. Given the roles of sigma-1 receptor in the early-stage of virus replication and ASM in virus entry, fluvoxamine would be a potential prophylactic drug, reducing clinical deterioration in COVID-19 patients. Importantly, it should be taken in persons with COVID-19 as quickly as possible after SARS-CoV-2 infection confirmation.

From the limited clinical data, fluvoxamine may be the most attractive candidate for early-stage COVID-19 patients. However, further randomized, multicenter, double-blind study using a large sample size is needed. Fluvoxamine has favorable safety profiles, widespread availability, and is very low cost administered orally and used for children and adolescents [22]. If fluvoxamine is used in the treatment of pregnant women with COVID-19, follow-up for the offspring is important. Several SARS-CoV-2-neutralizing monoclonal antibodies for mild to moderate symptoms in high-risk COVID-19 patients were approved [123]. Recently, Merck Sharp and Dohme reported that the novel oral antiviral drug molnupiravir reduced the risk of admission to hospital or death by around 50% in non-hospitalized adults [124]. It is possible that a combination of fluvoxamine with neutralizing monoclonal antibodies or molnupiravir may be more effective [125], although further study is needed. Finally, a cheap, widely available fluvoxamine would be a “game-changer” for people with COVID-19.